These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1151 related items for PubMed ID: 18483385

  • 21. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin KM, Fulda S.
    Cancer Res; 2008 Oct 01; 68(19):7956-65. PubMed ID: 18829553
    [Abstract] [Full Text] [Related]

  • 22. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J, Sui J, Demirjian A, Vollmer CM, Marasco W, Callery MP.
    Cancer Res; 2005 Mar 15; 65(6):2344-52. PubMed ID: 15781649
    [Abstract] [Full Text] [Related]

  • 23. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.
    Cancer Res; 2004 Jul 15; 64(14):4900-5. PubMed ID: 15256461
    [Abstract] [Full Text] [Related]

  • 24. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.
    Son YG, Kim EH, Kim JY, Kim SU, Kwon TK, Yoon AR, Yun CO, Choi KS.
    Cancer Res; 2007 Sep 01; 67(17):8274-84. PubMed ID: 17804742
    [Abstract] [Full Text] [Related]

  • 25. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Biochem Pharmacol; 2012 Mar 15; 83(6):769-77. PubMed ID: 22230479
    [Abstract] [Full Text] [Related]

  • 26. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
    Shi RX, Ong CN, Shen HM.
    Cancer Res; 2005 Sep 01; 65(17):7815-23. PubMed ID: 16140950
    [Abstract] [Full Text] [Related]

  • 27. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
    Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF, Thorne R, Zhang XD, Hersey P.
    Cancer Res; 2007 Jun 15; 67(12):5880-8. PubMed ID: 17575157
    [Abstract] [Full Text] [Related]

  • 28. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
    Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Möller P, Gschwend JE, Simmet T, Debatin KM, Fulda S.
    Cancer Res; 2009 Mar 15; 69(6):2425-34. PubMed ID: 19258513
    [Abstract] [Full Text] [Related]

  • 29. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole.
    Goda AE, Yoshida T, Horinaka M, Yasuda T, Shiraishi T, Wakada M, Sakai T.
    Oncogene; 2008 May 29; 27(24):3435-45. PubMed ID: 18193086
    [Abstract] [Full Text] [Related]

  • 30. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
    Petrucci E, Pasquini L, Petronelli A, Saulle E, Mariani G, Riccioni R, Biffoni M, Ferretti G, Benedetti-Panici P, Cognetti F, Scambia G, Humphreys R, Peschle C, Testa U.
    Gynecol Oncol; 2007 May 29; 105(2):481-92. PubMed ID: 17292950
    [Abstract] [Full Text] [Related]

  • 31. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
    Griffith TS, Kemp TJ.
    Cancer Chemother Pharmacol; 2003 Sep 29; 52(3):175-84. PubMed ID: 12811515
    [Abstract] [Full Text] [Related]

  • 32. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Miyashita K, Shiraki K, Fuke H, Inoue T, Yamanaka Y, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T.
    Int J Mol Med; 2006 Aug 29; 18(2):249-56. PubMed ID: 16820931
    [Abstract] [Full Text] [Related]

  • 33. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.
    Kusaba M, Nakao K, Goto T, Nishimura D, Kawashimo H, Shibata H, Motoyoshi Y, Taura N, Ichikawa T, Hamasaki K, Eguchi K.
    J Hepatol; 2007 Oct 29; 47(4):546-55. PubMed ID: 17602782
    [Abstract] [Full Text] [Related]

  • 34. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
    Wu XX, Kakehi Y.
    Clin Cancer Res; 2009 Mar 15; 15(6):2039-47. PubMed ID: 19276256
    [Abstract] [Full Text] [Related]

  • 35. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S, Liu X, Yue P, Schönthal AH, Khuri FR, Sun SY.
    Mol Pharmacol; 2007 Nov 15; 72(5):1269-79. PubMed ID: 17684158
    [Abstract] [Full Text] [Related]

  • 36. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH.
    Biochem Pharmacol; 2009 Apr 15; 77(8):1328-36. PubMed ID: 19426671
    [Abstract] [Full Text] [Related]

  • 37. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
    Kim YH, Jung EM, Lee TJ, Kim SH, Choi YH, Park JW, Park JW, Choi KS, Kwon TK.
    Free Radic Biol Med; 2008 Mar 15; 44(6):1055-68. PubMed ID: 18164688
    [Abstract] [Full Text] [Related]

  • 38. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).
    Guseva NV, Rokhlin OW, Taghiyev AF, Cohen MB.
    Breast Cancer Res Treat; 2008 Feb 15; 107(3):349-57. PubMed ID: 17453339
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
    Frese S, Schüller A, Frese-Schaper M, Gugger M, Schmid RA.
    Anticancer Res; 2009 Aug 15; 29(8):2905-11. PubMed ID: 19661294
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.